The dementia antipsychotic withdrawal trial dart-ad

Your Email Please enter the email address that the record information will be sent to. Your message optional Please add any additional information to be included within the email. The Lancet. Neurology, 8 2 , — Neurology, vol. Neurology 8 2 : — Access Document Publisher copy: Bibliographic data the information relating to research outputs and full-text items e.

Unfortunately we are not able to make available the full-text for every research output. Please contact the ORA team if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.

Version unsuitable We have not obtained a suitable full-text for a given research output. See this page for more information. Recently completed Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.

Permissions All content made available in ORA should comply with relevant rights, such as copyright. Clearance Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected. Your name. Your email We require your email address in order to let you know the outcome of your request.

Bodleian Card Number optional. An additional follow-up telephone assessment was done to establish whether each participant was still alive 24 months after the enrollment of the last participant range months.

Causes of death were obtained from death certificates. There was a reduction in survival in the patients who continued to receive antipsychotics compared with those who received placebo. The hazard ratio for the mITT group was 0.

Interpretation: There is an increased long-term risk of mortality in patients with AD who are prescribed antipsychotic medication; these results further highlight the need to seek less harmful alternatives for the long-term treatment of neuropsychiatric symptoms in these patients.

Abstract Background: Data from week placebo-controlled trials have led to mounting concerns about increased mortality in patients with Alzheimer's disease AD who are prescribed antipsychotics; however, there are no mortality data from long-term placebo-controlled trials.